$4.39
2.09% day before yesterday
Nasdaq, Aug 22, 10:18 pm CET

AbCellera Biologics Inc Target price 2025 - Analyst rating & recommendation

AbCellera Biologics Inc Classifications & Recommendation:

Buy
86%
Hold
14%

AbCellera Biologics Inc Price Target

Target Price $9.18
Price $4.39
Potential
Number of Estimates 9
9 Analysts have issued a price target AbCellera Biologics Inc 2026 . The average AbCellera Biologics Inc target price is $9.18. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 12 Analysts recommend AbCellera Biologics Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AbCellera Biologics Inc stock has an average upside potential 2026 of . Most analysts recommend the AbCellera Biologics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 28.83 21.57
24.19% 25.18%
EBITDA Margin -776.69% -1,109.69%
38.80% 42.87%
Net Margin -564.90% -946.17%
46.74% 67.49%

11 Analysts have issued a sales forecast AbCellera Biologics Inc 2025 . The average AbCellera Biologics Inc sales estimate is

$21.6m
Unlock
. This is
34.39% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$27.5m 16.33%
Unlock
, the lowest is
$15.7m 52.23%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $28.8m 24.19%
2025
$21.6m 25.18%
Unlock
2026
$36.9m 71.11%
Unlock
2027
$46.9m 27.11%
Unlock
2028
$147m 213.09%
Unlock
2029
$208m 41.47%
Unlock
2030
$249m 20.04%
Unlock
2031
$116m 53.39%
Unlock
2032
$129m 10.53%
Unlock

5 Analysts have issued an AbCellera Biologics Inc EBITDA forecast 2025. The average AbCellera Biologics Inc EBITDA estimate is

$-239m
Unlock
. This is
9.61% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-224m 2.51%
Unlock
, the lowest is
$-243m 11.10%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-224m 5.22%
2025
$-239m 6.90%
Unlock
2026
$-245m 2.41%
Unlock
2027
$-282m 15.13%
Unlock

EBITDA Margin

2024 -776.69% 38.80%
2025
-1,109.69% 42.87%
Unlock
2026
-664.15% 40.15%
Unlock
2027
-601.57% 9.42%
Unlock

11 AbCellera Biologics Inc Analysts have issued a net profit forecast 2025. The average AbCellera Biologics Inc net profit estimate is

$-204m
Unlock
. This is
23.20% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-182m 9.78%
Unlock
, the lowest is
$-222m 34.26%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-163m 11.24%
2025
$-204m 25.32%
Unlock
2026
$-178m 12.93%
Unlock
2027
$-215m 21.14%
Unlock
2028
$6.1m 102.83%
Unlock
2029
$110m 1,700.66%
Unlock
2030
$174m 58.34%
Unlock

Net Margin

2024 -564.90% 46.74%
2025
-946.17% 67.49%
Unlock
2026
-481.42% 49.12%
Unlock
2027
-458.84% 4.69%
Unlock
2028
4.15% 100.90%
Unlock
2029
52.77% 1,171.57%
Unlock
2030
69.61% 31.91%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.55 -0.68
7.84% 23.64%
P/E negative
EV/Sales 35.18

11 Analysts have issued a AbCellera Biologics Inc forecast for earnings per share. The average AbCellera Biologics Inc EPS is

$-0.68
Unlock
. This is
21.43% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.61 8.93%
Unlock
, the lowest is
$-0.74 32.14%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.55 7.84%
2025
$-0.68 23.64%
Unlock
2026
$-0.59 13.24%
Unlock
2027
$-0.72 22.03%
Unlock
2028
$0.02 102.78%
Unlock
2029
$0.37 1,750.00%
Unlock
2030
$0.58 56.76%
Unlock

P/E ratio

Current -7.84 59.19%
2025
-6.42 18.10%
Unlock
2026
-7.38 14.95%
Unlock
2027
-6.09 17.48%
Unlock
2028
215.20 3,633.66%
Unlock
2029
11.96 94.44%
Unlock
2030
7.55 36.87%
Unlock

Based on analysts' sales estimates for 2025, the AbCellera Biologics Inc stock is valued at an EV/Sales of

35.18
Unlock
and an P/S ratio of
60.82
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 23.08 671.91%
2025
35.18 52.41%
Unlock
2026
20.56 41.56%
Unlock
2027
16.17 21.33%
Unlock
2028
5.17 68.06%
Unlock
2029
3.65 29.31%
Unlock
2030
3.04 16.70%
Unlock
2031
6.53 114.52%
Unlock
2032
5.90 9.52%
Unlock

P/S ratio

Current 39.90 71.51%
2025
60.82 52.43%
Unlock
2026
35.54 41.56%
Unlock
2027
27.96 21.33%
Unlock
2028
8.93 68.06%
Unlock
2029
6.31 29.31%
Unlock
2030
5.26 16.70%
Unlock
2031
11.28 114.53%
Unlock
2032
10.21 9.52%
Unlock

Current AbCellera Biologics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Stifel
Locked
Locked
Locked Aug 08 2025
Keybanc
Locked
Locked
Locked Jul 14 2025
Truist Securities
Locked
Locked
Locked May 16 2025
Keybanc
Locked
Locked
Locked Apr 16 2025
Benchmark
Locked
Locked
Locked Mar 03 2025
Stifel
Locked
Locked
Locked Feb 28 2025
Keybanc
Locked
Locked
Locked Jan 08 2025
Analyst Rating Date
Locked
Stifel:
Locked
Locked
Aug 08 2025
Locked
Keybanc:
Locked
Locked
Jul 14 2025
Locked
Truist Securities:
Locked
Locked
May 16 2025
Locked
Keybanc:
Locked
Locked
Apr 16 2025
Locked
Benchmark:
Locked
Locked
Mar 03 2025
Locked
Stifel:
Locked
Locked
Feb 28 2025
Locked
Keybanc:
Locked
Locked
Jan 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today